mirikizumab vs picankibart
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline
mirikizumab · Omvoh
Marketed by Eli Lilly
NCT03524092 · Phase 3 · completed
Randomized (re-randomization of induction responders), double-blind, placebo-controlled, adequately powered (n=544 in the key comparison), hard composite clinical/endoscopic primary endpoint that was statistically significant in the favorable direction (p<0.001) — meeting the 'strong' definition's full test.
Next expected readout: May 2027 · NCT07186101 (registry estimate)
Reported efficacy
Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders): Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders) (Week 40): Maintenance Period: Miri IR - 200 mg Miri SC 49.9% (95% CI 44.7 to 55) vs Maintenance Period: Miri IR - PBO SC 25.1% (95% CI 18.8 to 31.5) (met)
Result source: NCT03524092
picankibart
Marketed by Innovent Biologics
NCT05377580 · Phase 2 · completed
This randomized, quadruple-blind, placebo-controlled Phase 2 trial enrolled 150 patients with moderately to severely active ulcerative colitis and tested several doses of picankibart against placebo. The primary endpoint was clinical remission at Week 12. The sponsor reported remission in 20.0% of patients on 200 mg and 14.0% on 600 mg versus 2.0% on placebo (p<0.05), so the primary endpoint was met; no power calculation or planned enrolment was found in the sources checked.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Evaluate the effectiveness of IBI112 in inducing clinical remission in patients with moderately to severely active ulcerative colitis (UC) (week 12): Week 12 clinical remission (primary endpoint): picankibart 200 mg 20.0% and 600 mg 14.0% vs placebo 2.0% (p<0.05). (met)
Result source: NCT05377580
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | mirikizumab | picankibart |
|---|---|---|
| Clinical remission (induction) | 24.2% vs 13.3%+10.9 vs placeboNCT035180863 other results
| —Not reported |
| Clinical remission (maintenance) | 49.9% vs 25.1%+24.8 vs placeboNCT03524092 | —Not reported |
| Clinical response (induction) | 63.5% vs 42.2%+21.3 vs placeboNCT035180863 other results
| —Not reported |
| Endoscopic improvement (induction) | 13.1% vs 6.3%+6.8 vs placeboNCT025896652 other results
| —Not reported |
| Corticosteroid-free remission (maintenance) | —Not posted · NCT05784246 | —Not reported |
Clinical remission (induction)
- mirikizumab
- 24.2% vs 13.3%+10.9 vs placeboNCT03518086
3 other results
- 11.5% vs 4.8% NCT02589665
- 22.6% vs 4.8% NCT02589665
- 15.9% vs 4.8% NCT02589665
- picankibart
- —Not reported
Clinical remission (maintenance)
- mirikizumab
- 49.9% vs 25.1%+24.8 vs placeboNCT03524092
- picankibart
- —Not reported
Clinical response (induction)
- mirikizumab
- 63.5% vs 42.2%+21.3 vs placeboNCT03518086
3 other results
- 49.2% vs 20.6% NCT02589665
- 59.7% vs 20.6% NCT02589665
- 41.3% vs 20.6% NCT02589665
- picankibart
- —Not reported
Endoscopic improvement (induction)
- mirikizumab
- 13.1% vs 6.3%+6.8 vs placeboNCT02589665
2 other results
- 30.6% vs 6.3% NCT02589665
- 23.8% vs 6.3% NCT02589665
- picankibart
- —Not reported
Corticosteroid-free remission (maintenance)
- mirikizumab
- —Not posted · NCT05784246
- picankibart
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. mirikizumab: 4 of 4 rows · picankibart: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | mirikizumab |
|---|---|
| Dropout rate | —300 mg IVa NCT03524092 · Phase 3 show 30 more results—300 mg IV NCT03524092 · Phase 3 —300 mg IV NCT03524092 · Phase 3 —300 mg IV NCT03524092 · Phase 3 —200 mg SC NCT03524092 · Phase 3 11.5%200 mg SC NCT03524092 · Phase 3 —200 mg SC NCT03524092 · Phase 3 —200 mg SC NCT03524092 · Phase 3 —300 mg IV Q4W NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 4.1%300 mg IV Q4W NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 7.2%300 mg IV Q4W NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 9.9%300 mg NCT05767021 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 0%300 mg IV NCT04004611 · Phase 2 · registry result, not featured evidence —300 mg IV NCT04004611 · Phase 2 · registry result, not featured evidence —300 mg IV / 200 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence —200 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence —100 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence 0%10 mg/kg IV NCT04004611 · Phase 2 · registry result, not featured evidence —10 mg/kg IV NCT04004611 · Phase 2 · registry result, not featured evidence —10 mg/kg IV / 100 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence —10 mg/kg IV / 50 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence —5 mg/kg IV NCT04004611 · Phase 2 · registry result, not featured evidence —5 mg/kg IV NCT04004611 · Phase 2 · registry result, not featured evidence —200 mg SC Q4W NCT02589665 · Phase 2 · registry result, not featured evidence —200 mg SC Q4W NCT02589665 · Phase 2 · registry result, not featured evidence —200 mg SC Q12W NCT02589665 · Phase 2 · registry result, not featured evidence —1000 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence —600 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence 6.6%600 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence 3.2%200 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence —50 mg Q4W NCT02589665 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —300 mg IVa NCT03524092 · Phase 3 show 30 more results—300 mg IV NCT03524092 · Phase 3 —300 mg IV NCT03524092 · Phase 3 —300 mg IV NCT03524092 · Phase 3 —200 mg SC NCT03524092 · Phase 3 7.7%200 mg SC NCT03524092 · Phase 3 —200 mg SC NCT03524092 · Phase 3 —200 mg SC NCT03524092 · Phase 3 —300 mg IV Q4W NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 1.6%300 mg IV Q4W NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 1.6%300 mg IV Q4W NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 1.2%300 mg NCT05767021 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —300 mg IV NCT04004611 · Phase 2 · registry result, not featured evidence —300 mg IV NCT04004611 · Phase 2 · registry result, not featured evidence —300 mg IV / 200 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence —200 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence —100 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence —10 mg/kg IV NCT04004611 · Phase 2 · registry result, not featured evidence —10 mg/kg IV NCT04004611 · Phase 2 · registry result, not featured evidence —10 mg/kg IV / 100 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence —10 mg/kg IV / 50 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence —5 mg/kg IV NCT04004611 · Phase 2 · registry result, not featured evidence —5 mg/kg IV NCT04004611 · Phase 2 · registry result, not featured evidence —200 mg SC Q4W NCT02589665 · Phase 2 · registry result, not featured evidence —200 mg SC Q4W NCT02589665 · Phase 2 · registry result, not featured evidence —200 mg SC Q12W NCT02589665 · Phase 2 · registry result, not featured evidence —1000 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence —600 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence 3.3%600 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence 3.2%200 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence —50 mg Q4W NCT02589665 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 5.2%300 mg IVa NCT03524092 · Phase 3 show 30 more results6.1%300 mg IV NCT03524092 · Phase 3 3.3%300 mg IV NCT03524092 · Phase 3 16.7%300 mg IV NCT03524092 · Phase 3 3.3%200 mg SC NCT03524092 · Phase 3 13.5%200 mg SC NCT03524092 · Phase 3 3.3%200 mg SC NCT03524092 · Phase 3 9.1%200 mg SC NCT03524092 · Phase 3 2.8%300 mg IV Q4W NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —300 mg IV Q4W NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 8%300 mg IV Q4W NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 2.9%300 mg NCT05767021 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 0%300 mg IV NCT04004611 · Phase 2 · registry result, not featured evidence 9.1%300 mg IV NCT04004611 · Phase 2 · registry result, not featured evidence —300 mg IV / 200 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence —200 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence —100 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence 0%10 mg/kg IV NCT04004611 · Phase 2 · registry result, not featured evidence 40%10 mg/kg IV NCT04004611 · Phase 2 · registry result, not featured evidence —10 mg/kg IV / 100 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence —10 mg/kg IV / 50 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence 0%5 mg/kg IV NCT04004611 · Phase 2 · registry result, not featured evidence 0%5 mg/kg IV NCT04004611 · Phase 2 · registry result, not featured evidence 4.4%200 mg SC Q4W NCT02589665 · Phase 2 · registry result, not featured evidence 4.3%200 mg SC Q4W NCT02589665 · Phase 2 · registry result, not featured evidence 2.2%200 mg SC Q12W NCT02589665 · Phase 2 · registry result, not featured evidence 5.2%1000 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence 3.1%600 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence 5%600 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence 3.2%200 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence 0%50 mg Q4W NCT02589665 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 300 mg IVa arthralgia 3.3% (placebo 4.2%) nasopharyngitis 3.3% (placebo 5.7%) headache 1.7% (placebo 1%) NCT03524092 · Phase 3 show 24 more results300 mg IV upper respiratory tract infection 9.1% (placebo 2.6%) anaemia 6.1% (placebo 4.7%) covid-19 6.1% (placebo 2.1%) NCT03524092 · Phase 3 300 mg IV anaemia 5.6% (placebo 4.7%) headache 5.6% (placebo 1%) arthralgia 3.3% (placebo 4.2%) NCT03524092 · Phase 3 300 mg IV covid-19 8.3% (placebo 2.1%) electrolyte imbalance 8.3% (placebo 0%) haemorrhoids 8.3% (placebo 1.6%) NCT03524092 · Phase 3 200 mg SC nasopharyngitis 7.2% (placebo 5.7%) arthralgia 6.7% (placebo 4.2%) colitis ulcerative 6.7% (placebo 18.2%) NCT03524092 · Phase 3 200 mg SC upper respiratory tract infection 15.4% (placebo 2.6%) covid-19 11.5% (placebo 2.1%) abdominal pain 7.7% (placebo 2.1%) NCT03524092 · Phase 3 200 mg SC arthralgia 7% (placebo 4.2%) nasopharyngitis 5.2% (placebo 5.7%) headache 4.8% (placebo 1%) NCT03524092 · Phase 3 200 mg SC uterine leiomyoma 14.3% (placebo 0%) upper respiratory tract infection 12.1% (placebo 2.6%) anorectal polyp 6.1% (placebo 1%) NCT03524092 · Phase 3 300 mg IV Q4W anaemia 3.2% (placebo 5.6%) colitis ulcerative 0% (placebo 0%) upper respiratory tract infection 0% (placebo 0%) NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 300 mg IV Q4W upper respiratory tract infection 12% (placebo 0%) anaemia 6.4% (placebo 5.6%) colitis ulcerative 2.4% (placebo 0%) NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 300 mg any event 7% any event 6.4% any event 5.8% NCT05767021 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 300 mg IV rash 18.2% dysmenorrhoea 16.7% arthralgia 9.1% NCT04004611 · Phase 2 · registry result, not featured evidence 300 mg IV injection site pain 27.3% asymptomatic covid-19 18.2% covid-19 18.2% NCT04004611 · Phase 2 · registry result, not featured evidence 10 mg/kg IV anaemia 20% covid-19 20% pollakiuria 20% NCT04004611 · Phase 2 · registry result, not featured evidence 10 mg/kg IV covid-19 40% anaemia 20% dyspepsia 20% NCT04004611 · Phase 2 · registry result, not featured evidence 5 mg/kg IV headache 30% pyrexia 20% abdominal pain upper 10% NCT04004611 · Phase 2 · registry result, not featured evidence 5 mg/kg IV headache 30% covid-19 20% injection site pain 20% NCT04004611 · Phase 2 · registry result, not featured evidence 200 mg SC Q4W nasopharyngitis 20.6% (placebo 9.5%) colitis ulcerative 10.3% (placebo 9.5%) back pain 8.8% (placebo 0%) NCT02589665 · Phase 2 · registry result, not featured evidence 200 mg SC Q4W arthralgia 12.8% (placebo 0%) nasopharyngitis 12.8% (placebo 9.5%) headache 10.6% (placebo 4.8%) NCT02589665 · Phase 2 · registry result, not featured evidence 200 mg SC Q12W nasopharyngitis 17.4% (placebo 9.5%) colitis ulcerative 15.2% (placebo 9.5%) influenza 8.7% (placebo 0%) NCT02589665 · Phase 2 · registry result, not featured evidence 1000 mg IV Q4W nasopharyngitis 7.3% (placebo 9.5%) dry skin 1% (placebo 0%) abdominal discomfort 0% (placebo 0%) NCT02589665 · Phase 2 · registry result, not featured evidence 600 mg IV Q4W nasopharyngitis 15.6% (placebo 9.5%) influenza 9.4% (placebo 0%) dry skin 6.3% (placebo 0%) NCT02589665 · Phase 2 · registry result, not featured evidence 600 mg IV Q4W nasopharyngitis 8.3% (placebo 9.5%) headache 6.7% (placebo 4.8%) nausea 5% (placebo 6.3%) NCT02589665 · Phase 2 · registry result, not featured evidence 200 mg IV Q4W nasopharyngitis 4.8% (placebo 9.5%) anaemia 3.2% (placebo 4.8%) nausea 3.2% (placebo 6.3%) NCT02589665 · Phase 2 · registry result, not featured evidence 50 mg Q4W nasopharyngitis 7.9% (placebo 9.5%) anaemia 6.3% (placebo 4.8%) headache 4.8% (placebo 4.8%) NCT02589665 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 27 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
mirikizumab
show 2 more results
show 2 more results
show 3 more results
show 3 more results
show 3 more results
+ 30 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: mirikizumab's landscape · picankibart's landscape